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In this issue McIver et al document in men who have sex with men (MSM)  with nongonococcal 
urethritis (NGU) an increase in Mycoplasma genitalium (Mgen) positivity from 4.5% to 12.8% over a 
12 yr period.(1) Mgen was observed to be as common in MSM with NGU as men who have sex with 
women (MSW), which has not been observed previously.(2) High rates of Mgen macrolide 
antimicrobial resistance  (MAMR) were also observed which was significantly higher in MSM (89.7%) 
with NGU compared to MSW (50%).  They speculate that the higher MAMR  among MSM, probably 
reflects that MSM are more likely to be  exposed to azithromycin because they test more frequently 
and have higher rates of  sexually transmissible infections (STIs) compared to the general population. 
Although their study design differed from the historical comparison in that in this study men with 
urethral irritation but no symptoms of urethral discharge or dysuria were excluded, in whom Mgen is 
less commonly detected, this would only account  for only a small part of the increase in 
positivity.(2) The authors go on to conclude that their observations support recommendations to 
test all men with NGU for M.  genitalium and to incorporate real-time resistance assays into clinical 




During the past 20 years the sexual behaviour of MSM has changed with an increase in unprotected 
anal intercourse (UPAI) with both regular and casual partners.(3-6) This has been associated with a 
continued  increase in gonorrhoea,  syphilis and chlamydia and until recently substantial ongoing HIV 
transmission despite condom use continuing to be a key component of prevention initiatives.(7, 8) 
While the increase in these three bacterial STIs  may in part be  due to better detection of chlamydia 
and gonorrhoea in the earlier part of this decade it is believed that this increase  in the number of 
UPAI  partners as a result of behaviours such as HIV sero-adaptive behaviours, group sex facilitated 




effective antiretroviral therapy based control strategies such as treatment as prevention and more 
recently pre-exposure prophylaxis (PrEP) have seen substantial falls in HIV incidence in the United 
Kingdom despite this increase in UPAI.(8)  There is a concern that PrEP will increase unsafe sex in 
users and there is some evidence to support that this might happen in some but not all persons 
taking PrEP.(9, 10) 
 
Given that these 3 bacterial STIs have increased it should be no surprise that Mgen has also 
increased in MSM. Mgen is only rarely carried in the pharynx, so MSM with Mgen NGU will have 
predominantly acquired it through UPAI.(11-13) The basic reproductive number R0 i.e. the average 
number of secondary infections generated by one infectious individual in an entirely susceptible 




Where c denotes the average rate of partner change, β records the transmission probability per 
partnership, and D is the mean duration of infectiousness.(14) Thus for MSM both the average rate 
of partner change and the risk of transmission will have increased over time which, assuming no 
change in the duration of infection, would result in an increase in rectal carriage which is 
predominantly asymptomatic.(15-17) There is limited empirical evidence to support this but what 
there is, is consistent with this hypothesis. Bradshaw et al observed in high risk MSM attending a 
Melbourne sauna in 2000-2001 a rectal prevalence of 1.6% and in 2016-17 Read et al observed a 
rectal prevalence of 7% in asymptomatic men attending the Melbourne Sexual Health clinic. (16, 18) 
Asymptomatic carriage appears to be higher in the rectum than the urethra, suggesting that 
duration of infection may be longer in the rectum than the urethra. (15, 16, 18) Although biologically 
it would seem likely that Mgen causes proctitis at least in some men, a recent  case control study 




evidence that screening would result in a decrease in prevalence in MSM and does more good than 
harm.(12, 16, 17) 
Mgen prevalence in Australia is relatively high in asymptomatic high risk MSM (>7%) and partner 
change frequent, 2->16 every 3 months. (9, 16, 19)  Thus exposure  of MSM practising unsafe sex  to 
Mgen, will not be uncommon. Given the persistence of sub minimum inhibitory concentration (MIC) 
of azithromycin for at least 2-4 weeks following treatment with higher levels intra-cellularly than 
extracellularly this is probably also  a source of selection pressure for MAMR in Mgen in MSM 
recently treated with azithromycin.(20) A recent meta-analysis concluded that 12% of Mgen 
infections will develop macrolide resistance following treatment with azithromycin 1g.(21)  
Azithromycin in Australia at the time of the study was the treatment of choice for Mgen,  for NGU,  
for chlamydia, and part of dual therapy for Neisseria gonorrhoeae in which  Mgen co-infection is 
common ~10%.(1, 16) McIver et al.  and other experts attribute the high prevalence of macrolide 
resistance in Mgen in Australia to both treatment of Mgen and NGU with azithromycin and 
inadvertent exposure when treating other infections.(1, 16) There is little information on the 
proportion of MSM who receive treatment with azithromycin annually. In this study by McIver et 
al.(1) 24% of MSM had received azithromycin in the previous year, which is likely to be an 
overestimate for MSM as a whole, as not all MSM will attend a sexual health departments annually 
for screening. Nevertheless, if we assume 24% are treated with azithromycin every year and of these 
12% develop resistance then only  (0.24x 0.12)2.88% of all infections would develop resistance 
which over 10 yrs would result in (1- 0.971210) 25.4% and 35.5% MAMR over 15yrs, substantially 
lower than the 89.7% resistance rate reported in the McIver study.(1, 21) Clearly this is a simplistic 
analysis which does not reflect the dynamic nature of sexual transmission but it does suggest that 
selection pressure from direct treatment cannot by itself explain the rapid increase in MAMR Mgen 
which has occurred over the past 15 yrs.(1, 12, 16, 17, 20, 22, 23) The prolonged persistence of sub-
MIC levels following azithromycin treatment  could theoretically promote induction or selection of 




intercourse with  an untreated partner or a new partner who is infected with Mgen which is not 
uncommon in MSM (see above). (9, 16, 19, 20) How long this MAMR selection pressure could 
potentially persist for following azithromycin treatment is uncertain, BASHH has recommended 2 
weeks but it could be as long as 4 weeks.(12, 20, 24) However, there is only limited evidence to 
support this hypothesis and although no association with previous azithromycin use and MAMR was 
found by McIver et al or in the study by Read et al., this probably reflects the high background 
MAMR in MSM.(1, 16) This hypothesis would benefit from an evaluation using mathematical 
modelling as it has implications for patient management and how long patients should abstain from 
sexual intercourse following azithromycin treatment.(12, 20, 25) 
Given the asymptomatic nature of Mgen, the high rates of partner change and carriage in high risk 
MSM and  increasing MAMR, it is likely that mixed infections of macrolide sensitive and resistant 
infections are occurring.  MAMR nucleic acid amplification tests (NAATs) will miss some infections 
containing low numbers of MAMR micro-organisms and conversely are likely to identify infections as 
resistant when the majority of micro-organisms are sensitive.(19, 26) The former could at least in 
part explain why the observation that extended azithromycin  1.5g was associated with higher 
treatment failure due to selection for MAMR in MSM from a high MAMR Mgen prevalent population 
compared to low prevalent populations. (17, 19, 21, ) While the latter could potentially explain why 
azithromycin 1 g is clinically effective in some cases of apparent MAMR Mgen by reducing the load 
but does not eradicate the infection.(27) Clearly a better understanding of the natural history of 
Mgen including duration of infection in the urethra and rectum, risk of transmission, risk of 
developing disease and how this is influenced by load and the pharmacokinetics of antimicrobials 
and the lowest  MIC at which a selection pressure  in Mgen occurs would better inform 
mathematical models and improve our understanding of the most effective strategies for managing 




In conclusion, this study provides further evidence for  treating all men with NGU with doxycycline 
and testing them for Mgen in order to enable resistance guided therapy if found to be Mgen-
positive.(12, 17,  26, 27) When extended azithromycin is used to treat macrolide sensitive infections 
patients should be advised not to be sexually active for at least 2 weeks and possibly 4 because of 
the risk of re-exposure to Mgen particularly in high prevalence networks.(12)  It also provides 
support for the recent approach adopted in the UK of discontinuing the  use of azithromycin 1 g to 
treat chlamydia, Mgen, gonorrhoea and NGU. (https://www.bashh.org/guidelines) Mgen is likely to 
continue to increase as a cause of NGU in MSM with high rates of partner change and practising 
UPAI and there is no evidence that screening could avert this and does more good than harm. (12, 
17)  Finally a better understanding of the natural history of Mgen infection and antimicrobial 
pharmacokinetics would help inform public health control measures in addition to the continued 
promotion of condom use and improve the efficacy of antimicrobial treatment regimens and reduce 
the risk of Mgen AMR developing. (20, 25, 27) 
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